Age 0 3 0 3 B-age
≥ 4 5 4 5 O
18 6 8 6 8 B-lower_bound
years 9 14 9 14 I-lower_bound

Diagnostic 0 10 15 25 O
contrast 11 19 26 34 B-treatment
- 19 20 34 35 I-treatment
enhanced 20 28 35 43 I-treatment
MRI 29 32 44 47 I-treatment
or 33 35 48 50 O
CT 36 38 51 53 B-treatment
scan 39 43 54 58 I-treatment
of 44 46 59 61 I-treatment
the 47 50 62 65 I-treatment
brain 51 56 66 71 I-treatment
preoperatively 57 71 72 86 O
and 72 75 87 90 O
postoperatively 76 91 91 106 O

Did 0 3 107 110 O
not 4 7 111 114 O
start 8 13 115 120 O
radiation 14 23 121 130 B-treatment
therapy 24 31 131 138 I-treatment
and 32 35 139 142 O
temozolomide 36 48 143 155 B-treatment
within 49 55 156 162 O
7 56 57 163 164 B-upper_bound
weeks 58 63 165 170 I-upper_bound
of 64 66 171 173 O
surgery 67 74 174 181 B-treatment

For 0 3 182 185 O
females 4 11 186 193 B-gender
of 12 14 194 196 O
childbearing 15 27 197 209 O
potential 28 37 210 219 O
, 37 38 219 220 O
negative 39 47 221 229 B-pregnancy
serum 48 53 230 235 I-pregnancy
pregnancy 54 63 236 245 I-pregnancy
test 64 68 246 250 O

For 0 3 251 254 O
patients 4 12 255 263 O
receiving 13 22 264 273 O
steroids 23 31 274 282 B-treatment
, 31 32 282 283 O
daily 33 38 284 289 B-clinical_variable
dose 39 43 290 294 I-clinical_variable
must 44 48 295 299 O
be 49 51 300 302 O
≤ 52 53 303 304 O
4 54 55 305 306 B-upper_bound
mg 56 58 307 309 I-upper_bound

HIV 0 3 310 313 B-chronic_disease
, 3 4 313 314 O
Hepatitis 5 14 315 324 B-chronic_disease
B 15 16 325 326 I-chronic_disease
, 16 17 326 327 O
or 18 20 328 330 O
Hepatitis 21 30 331 340 B-chronic_disease
C 31 32 341 342 I-chronic_disease
seropositive 33 45 343 355 O

Histopathologically 0 19 356 375 O
proven 20 26 376 382 O
newly 27 32 383 388 O
- 32 33 388 389 O
diagnosed 33 42 389 398 O
de 43 45 399 401 B-cancer
novo 46 50 402 406 I-cancer
GBM 51 54 407 410 I-cancer
( 55 56 411 412 O
WHO 56 59 412 415 O
Grade 60 65 416 421 B-cancer
IV 66 68 422 424 I-cancer
glioma 69 75 425 431 I-cancer
) 75 76 431 432 O

History 0 7 433 440 O
& 8 9 441 442 O
physical 10 18 443 451 O
with 19 23 452 456 O
neurologic 24 34 457 467 O
examination 35 46 468 479 O
prior 47 52 480 485 O
to 53 55 486 488 O
initiation 56 66 489 499 O
of 67 69 500 502 O
adjuvant 70 78 503 511 B-treatment
TMZ 79 82 512 515 I-treatment

Karnofsky 0 9 516 525 B-clinical_variable
Performance 10 21 526 537 I-clinical_variable
Status 22 28 538 544 I-clinical_variable
of 29 31 545 547 O
≥ 32 33 548 549 O
70 34 36 550 552 B-lower_bound

Known 0 5 553 558 O
active 6 12 559 565 B-chronic_disease
infection 13 22 566 575 I-chronic_disease
or 23 25 576 578 O
immunosuppressive 26 43 579 596 B-chronic_disease
disease 44 51 597 604 I-chronic_disease

Metastases 0 10 605 615 B-cancer
detected 11 19 616 624 O
below 20 25 625 630 O
the 26 29 631 634 O
tentorium 30 39 635 644 B-treatment
or 40 42 645 647 O
beyond 43 49 648 654 O
the 50 53 655 658 O
cranial 54 61 659 666 O
vault 62 67 667 672 O
and 68 71 673 676 O
leptomeningeal 72 86 677 691 O
involvement 87 98 692 703 O

More 0 4 704 708 O
than 5 9 709 713 O
45 10 12 714 716 B-lower_bound
days 13 17 717 721 I-lower_bound
after 18 23 722 727 B-treatment
completion 24 34 728 738 I-treatment
of 35 37 739 741 I-treatment
radiation 38 47 742 751 I-treatment
therapy 48 55 752 759 I-treatment
and 56 59 760 763 O
temozolomide 60 72 764 776 B-treatment

Must 0 4 777 781 O
have 5 9 782 786 O
completed 10 19 787 796 O
RT 20 22 797 799 B-treatment
( 23 24 800 801 O
targeted 24 32 801 809 O
total 33 38 810 815 O
dose 39 43 816 820 O
of 44 46 821 823 O
59.4 47 51 824 828 B-lower_bound
- 51 52 828 829 O
60.0 52 56 829 833 B-upper_bound
Gy 57 59 834 836 I-upper_bound
over 60 64 837 841 O
≤ 65 66 842 843 O
7 67 68 844 845 B-upper_bound
weeks 69 74 846 851 I-upper_bound
) 74 75 851 852 O
and 76 79 853 856 O
concomitant 80 91 857 868 O
TMZ 92 95 869 872 B-treatment
( 96 97 873 874 O
targeted 97 105 874 882 O
dose 106 110 883 887 O
of 111 113 888 890 O
75mg 114 118 891 895 O
/ 118 119 895 896 O
m2 119 121 896 898 O
/ 121 122 898 899 O
d 122 123 899 900 O
for 124 127 901 904 O
≤ 128 129 905 906 O
49 130 132 907 909 B-upper_bound
days 133 137 910 914 I-upper_bound
) 137 138 914 915 O
therapy 139 146 916 923 B-treatment
without 147 154 924 931 O
significant 155 166 932 943 O
toxicity 167 175 944 952 O
that 176 180 953 957 O
persisted 181 190 958 967 O
over 191 195 968 972 O
4 196 197 973 974 B-lower_bound
weeks 198 203 975 980 I-lower_bound

Must 0 4 981 985 O
have 5 9 986 990 O
undergone 10 19 991 1000 O
definitive 20 30 1001 1011 B-treatment
surgical 31 39 1012 1020 I-treatment
resection 40 49 1021 1030 I-treatment
of 50 52 1031 1033 O
tumor 53 58 1034 1039 B-cancer
with 59 63 1040 1044 O
less 64 68 1045 1049 O
than 69 73 1050 1054 O
approximately 74 87 1055 1068 O
3 88 89 1069 1070 B-lower_bound
cm 89 91 1070 1072 I-lower_bound
x 92 93 1073 1074 I-lower_bound
3 94 95 1075 1076 I-lower_bound
cm 95 97 1076 1078 I-lower_bound
residual 98 106 1079 1087 O
enhancing 107 116 1088 1097 O
tumor 117 122 1098 1103 O
as 123 125 1104 1106 O
product 126 133 1107 1114 O
of 134 136 1115 1117 O
longest 137 144 1118 1125 O
perpendicular 145 158 1126 1139 O
planes 159 165 1140 1146 O
by 166 168 1147 1149 O
MRI 169 172 1150 1153 B-treatment

Patients 0 8 1154 1162 O
treated 9 16 1163 1170 O
on 17 19 1171 1173 O
any 20 23 1174 1177 O
other 24 29 1178 1183 B-treatment
therapeutic 30 41 1184 1195 I-treatment
clinical 42 50 1196 1204 I-treatment
protocols 51 60 1205 1214 I-treatment
within 61 67 1215 1221 O
30 68 70 1222 1224 B-upper_bound
days 71 75 1225 1229 I-upper_bound
prior 76 81 1230 1235 I-upper_bound
to 82 84 1236 1238 O
study 85 90 1239 1244 O
entry 91 96 1245 1250 O

Pregnancy 0 9 1251 1260 B-pregnancy

Pregnant 0 8 1261 1269 B-pregnancy

Prior 0 5 1270 1275 O
allergic 6 14 1276 1284 O
reaction 15 23 1285 1293 O
to 24 26 1294 1296 O
temozolomide 27 39 1297 1309 B-allergy_name
, 39 40 1309 1310 O
GM 41 43 1311 1313 B-allergy_name
- 43 44 1313 1314 I-allergy_name
CSF 44 47 1314 1317 I-allergy_name
or 48 50 1318 1320 O
Td 51 53 1321 1323 B-allergy_name

Prior 0 5 1324 1329 B-treatment
chemotherapy 6 18 1330 1342 I-treatment
or 19 21 1343 1345 O
radiosensitizers 22 38 1346 1362 B-treatment
( 39 40 1363 1364 O
including 40 49 1364 1373 O
Gliadel 50 57 1374 1381 B-treatment
wafers 58 64 1382 1388 I-treatment
) 64 65 1388 1389 O
for 66 69 1390 1393 O
cancers 70 77 1394 1401 B-cancer
of 78 80 1402 1404 I-cancer
the 81 84 1405 1408 I-cancer
head 85 89 1409 1413 I-cancer
and 90 93 1414 1417 I-cancer
neck 94 98 1418 1422 I-cancer
region 99 105 1423 1429 O

Prior 0 5 1430 1435 O
history 6 13 1436 1443 O
of 14 16 1444 1446 O
brachial 17 25 1447 1455 B-chronic_disease
neuritis 26 34 1456 1464 I-chronic_disease
or 35 37 1465 1467 O
Guillain 38 46 1468 1476 B-chronic_disease
- 46 47 1476 1477 I-chronic_disease
Barré 47 52 1477 1482 I-chronic_disease
syndrome 53 61 1483 1491 I-chronic_disease

Prior 0 5 1492 1497 O
invasive 6 14 1498 1506 B-cancer
malignancy 15 25 1507 1517 I-cancer
unless 26 32 1518 1524 O
disease 33 40 1525 1532 O
free 41 45 1533 1537 O
for 46 49 1538 1541 O
≥ 50 51 1542 1543 O
3 52 53 1544 1545 B-lower_bound
years 54 59 1546 1551 I-lower_bound

Prior 0 5 1552 1557 B-treatment
radiotherapy 6 18 1558 1570 I-treatment
to 19 21 1571 1573 O
the 22 25 1574 1577 O
head 26 30 1578 1582 O
or 31 33 1583 1585 O
neck 34 38 1586 1590 O
, 38 39 1590 1591 O
resulting 40 49 1592 1601 O
in 50 52 1602 1604 O
overlap 53 60 1605 1612 O
of 61 63 1613 1615 O
radiation 64 73 1616 1625 O
fields 74 80 1626 1632 O

Recovery 0 8 1633 1641 O
from 9 13 1642 1646 O
the 14 17 1647 1650 O
effects 18 25 1651 1658 O
of 26 28 1659 1661 O
surgery 29 36 1662 1669 B-treatment
, 36 37 1669 1670 O
postoperative 38 51 1671 1684 B-chronic_disease
infection 52 61 1685 1694 I-chronic_disease
, 61 62 1694 1695 O
and 63 66 1696 1699 O
other 67 72 1700 1705 O
complications 73 86 1706 1719 O

Recurrent 0 9 1720 1729 B-cancer
or 10 12 1730 1732 I-cancer
multifocal 13 23 1733 1743 I-cancer
malignant 24 33 1744 1753 I-cancer
gliomas 34 41 1754 1761 I-cancer

The 0 3 1762 1765 O
tumor 4 9 1766 1771 B-cancer
must 10 14 1772 1776 O
have 15 19 1777 1781 O
a 20 21 1782 1783 O
supratentorial 22 36 1784 1798 O
component 37 46 1799 1808 O

Women 0 5 1809 1814 B-gender
of 6 8 1815 1817 O
childbearing 9 21 1818 1830 O
potential 22 31 1831 1840 O
and 32 35 1841 1844 O
male 36 40 1845 1849 B-gender
participants 41 53 1850 1862 I-gender
must 54 58 1863 1867 O
be 59 61 1868 1870 O
willing 62 69 1871 1878 B-contraception_consent
to 70 72 1879 1881 I-contraception_consent
practice 73 81 1882 1890 I-contraception_consent
adequate 82 90 1891 1899 I-contraception_consent
contraception 91 104 1900 1913 I-contraception_consent
throughout 105 115 1914 1924 O
the 116 119 1925 1928 O
study 120 125 1929 1934 O
and 126 129 1935 1938 O
for 130 133 1939 1942 O
at 134 136 1943 1945 O
least 137 142 1946 1951 O
24 143 145 1952 1954 B-lower_bound
weeks 146 151 1955 1960 I-lower_bound
after 152 157 1961 1966 I-lower_bound
the 158 161 1967 1970 O
last 162 166 1971 1975 O
dose 167 171 1976 1980 O
of 172 174 1981 1983 O
study 175 180 1984 1989 B-treatment
drug 181 185 1990 1994 I-treatment

lactating 0 9 1995 2004 O
women 10 15 2005 2010 B-gender

men 0 3 2011 2014 B-gender
who 4 7 2015 2018 O
are 8 11 2019 2022 O
sexually 12 20 2023 2031 O
active 21 27 2032 2038 O
and 28 31 2039 2042 O
not 32 35 2043 2046 B-contraception_consent
willing 36 43 2047 2054 I-contraception_consent
/ 43 44 2054 2055 I-contraception_consent
able 44 48 2055 2059 I-contraception_consent
to 49 51 2060 2062 I-contraception_consent
use 52 55 2063 2066 I-contraception_consent
medically 56 65 2067 2076 I-contraception_consent
acceptable 66 76 2077 2087 I-contraception_consent
forms 77 82 2088 2093 I-contraception_consent
of 83 85 2094 2096 I-contraception_consent
contraception 86 99 2097 2110 I-contraception_consent
for 100 103 2111 2114 O
the 104 107 2115 2118 O
entire 108 114 2119 2125 O
study 115 120 2126 2131 O
period 121 127 2132 2138 O

women 0 5 2139 2144 B-gender
of 6 8 2145 2147 O
childbearing 9 21 2148 2160 O
potential 22 31 2161 2170 O

